CRCM  Vol.4 No.4 , April 2015
Trastuzumab Re-Introduction with FOLFIRI for Treatment of HER2 Overexpression-Advanced Gastric Adenocarcinoma Following Failure of Other Trastuzumab-Based Chemotherapy Regimens
Abstract: A 67-year-old man diagnosed with HER2 overexpression advanced gastric adenocarcinoma and metastasis to liver and lungs was admitted for tertiary care. He received a third line chemotherapy that consists of trastuzumab combined with FOLFIRI regimen (irinotecan plus 5-FU/LV) following a disease relapse after an initial successful response to a combination of 5FU + oxaliplatin and trastuzumab. The patient showed a favorable and prolonged response to it. In addition the chemotherapy was well tolerated and devoid of remarkable side effects. The response to trastuzumab + FOLFIRI was assessed clinically and through CT scan imaging and upper gastrointestinal endoscopy. This case report shows that firstly the combination of FOLFIRI and trastuzumab could be tested as another regimen in metastatic gastric cancer, and, secondly, that in this disease, like in metastatic breast cancer, the continuation of trastuzumab after an initial progression under this antibody could be tested in order to improve the efficacy of the treatment Trastuzumab re-introduction with FOLFIRI for treatment of HER2 overexpression-advanced gastric adenocarcinoma following failure of other trastuzumab-based chemotherapy regimens.
Cite this paper: Dubreuil, O. , Zaanan, A. , Pellerin, O. , Bachet, J. , Rougier, P. and Taieb, J. (2015) Trastuzumab Re-Introduction with FOLFIRI for Treatment of HER2 Overexpression-Advanced Gastric Adenocarcinoma Following Failure of Other Trastuzumab-Based Chemotherapy Regimens. Case Reports in Clinical Medicine, 4, 131-136. doi: 10.4236/crcm.2015.44028.

[1]   Jemal, A., Bray, F., Center, M.M., Ferlay, J., Ward, E. and Forman, D. (2011) Global Cancer Statistics. CA: A Cancer Journal for Clinicians, 61, 69-90.

[2]   Waters, J.S., Norman, A., Cunningham, D., Scarffe, J.H., Webb, A., Harper, P., et al. (1999) Long-Term Survival after Epirubicin, Cisplatin and Fluorouracil for Gastric Cancer: Results of a Randomized Trial. British Journal of Cancer, 80, 269-272.

[3]   Van Cutsem, E., Moiseyenko, V.M., Tjulandin, S., Majlis, A., Constenla, M., Boni, C., et al. (2006) Phase III Study of Docetaxel and Cisplatin plus Fluorouracil Compared with Cisplatin and Fluorouracil as First-Line Therapy for Advanced Gastric Cancer: A Report of the V325 Study Group. Journal of Clinical Oncology, 24, 4991-4997.

[4]   Al-Batran, S.-E., Hartmann, J.T., Probst, S., Schmalenberg, H., Hollerbach, S., Hofheinz, R., et al. (2008) Phase III Trial in Metastatic Gastroesophageal Adenocarcinoma with Fluorouracil, Leucovorin plus Either Oxaliplatin or Cisplatin: A Study of the Arbeitsgemeinschaft Internistische Onkologie. Journal of Clinical Oncology, 26, 1435-1442.

[5]   Guimbaud, R., Louvet, C., Ries, P., Ychou, M., Maillard, E., André, T., et al. (2014) Prospective, Randomized, Multicenter, Phase III Study of Fluorouracil, Leucovorin, and Irinotecan versus Epirubicin, Cisplatin, and Capecitabine in Advanced Gastric Adenocarcinoma: A French Intergroup (Fédération Francophone de Cancérologie Digestive, Fédération Nationale des Centres de Lutte Contre le Cancer, and Groupe Coopérateur Multidisciplinaire en Oncologie) Study. Journal of Clinical Oncology, 32, 3520-3526.

[6]   Bang, Y.-J., Van Cutsem, E., Feyereislova, A., Chung, H.C., Shen, L., Sawaki, A., et al. (2010) Trastuzumab in Combination with Chemotherapy versus Chemotherapy Alone for Treatment of HER2-Positive Advanced Gastric or Gastro-Oesophageal Junction Cancer (ToGA): A Phase 3, Open-Label, Randomised Controlled Trial. The Lancet, 376, 687-697.

[7]   Sun, J., Pan, S., Chen, Q., Gao, X. and Li, W. (2011) Efficacy of Trsatuzumab (Herceptin) Combined with FOLFIRI Regimen in the Treatment of HER2-Positive Advanced Gastric Cancer. Nan Fang Yi Ke Da Xue Xue Bao, 31, 1458-1460.

[8]   Weissinger, F., Reymond, M., Dumke, K. and Krüger, M. (2011) Successful Treatment of a Patient with HER2-Positive Metastatic Gastric Cancer with Third-Line Combination Therapy with Irinotecan, 5-Fluorouracil, Leucovorin and Trastuzumab (FOLFIRI-T). Onkologie, 34, 548-551.

[9]   Yamade, M., Sugimoto, M., Nishino, M., Uotani, T., Sahara, S., Iwaizumi, M., et al. (2012) Trastuzumab Has Opposing Effects on SN-38-Induced Double-Strand Breaks and Cytotoxicity in HER2-Positive Gastric Cancer Cells Depending on Administration Sequence. Anticancer Research, 32, 105-114.

[10]   Cancello, G., Montagna, E., D’Agostino, D., Giuliano, M., Giordano, A., Di Lorenzo, G., et al. (2008) Continuing Trastuzumab beyond Disease Progression: Outcomes Analysis in Patients with Metastatic Breast Cancer. Breast Cancer Research, 10, R60.

[11]   Extra, J.-M., Antoine, E.C., Vincent-Salomon, A., Delozier, T., Kerbrat, P., Bethune-Volters, A., et al. (2010) Efficacy of Trastuzumab in Routine Clinical Practice and after Progression for Metastatic Breast Cancer Patients: The Observational Hermine Study. Oncologist, 15, 799-809.

[12]   Von Minckwitz, G., du Bois, A., Schmidt, M., Maass, N., Cufer, T., de Jongh, F.E., et al. (2009) Trastuzumab beyond Progression in Human Epidermal Growth Factor Receptor 2-Positive Advanced Breast Cancer: A German Breast Group 26/Breast International Group 03-05 Study. Journal of Clinical Oncology, 27, 1999-2006.

[13]   Santini, D., Vincenzi, B., Addeo, R., Garufi, C., Masi, G., Scartozzi, M., et al. (2012) Cetuximab Rechallenge in Metastatic Colorectal Cancer Patients: How to Come Away from Acquired Resistance? Annals of Oncology, 23, 2313-2318.

[14]   Sakai, D., Satoh, T., Kurokawa, Y., Kudo, T., Nishikawa, K., Oka, Y., et al. (2013) A Phase II Trial of Trastuzumab Combined with Irinotecan in Patients with Advanced HER2-Positive Chemo-Refractory Gastric Cancer: Osaka Gastro-intestinal Cancer Chemotherapy Study Group OGSG1203 (HERBIS-5). Japanese Journal of Clinical Oncology, 43, 838-840.